Objective To investigate the effect of Albumin-bound Paclitaxel combined with Bevacizumab in patients with advanced ovarian cancer who failed second-line therapy. Methods From January 2020 to April 2021, 136 patients with advanced ovarian cancer who had failed second-line treatment admitted to the No.908 Hospital, Joint Logistics Support Force were selected as the research subjects. According to computer random number method, the patients were divided into control group (68 cases) and observation group (68 cases). The control group were treated with Albuminbound Paclitaxel, and the observation group was treated with Albumin-bound Paclitaxel combined with Bevacizumab.The treatment effect, serum carcinoembryonic antigen (CEA), serum glucose chain antigen 125 (CA125) levels and the incidence of adverse reactions were compared between the two groups. Results The total effective rate of observation group was higher than that of control group, and the difference was statistically significant (P＜0.05). After treatment, the levels of CEA and CA125 in the observation group were lower than those in the control group, and the differences were statistically significant (P＜0.05). There was no statistically significant difference in the overall incidence of adverse reactions between the two groups (P＞0.05). Conclusion For patients with advanced ovarian cancer who failed the secondline treatment, the treatment with Albumin-bound Paclitaxel combined with Bevacizumab has a good effect, can effectively improve the CEA and CA125 levels of patients, and has high safety and can be reasonable promotion and use should be carried out in combination with actual clinical needs.